Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Integra Lifesciences Narrows FY2025 Adj EPS Guidance from $2.19-$2.29 to $2.19-$2.24 vs $2.21 Est; Lowers FY2025 Sales Guidance from $1.655B-$1.680B to $1.620B-$1.640B vs $1.669B Est

Author: Benzinga Newsdesk | October 30, 2025 05:01am
Integra Lifesciences (NASDAQ:IART) narrows FY2025 Adj EPS guidance from $2.19-$2.29 to $2.19-$2.24 vs $2.21 analyst estimate. Lowers FY2025 sales outlook from $1.655 billion-$1.680 billion to $1.620 billion-$1.640 billion vs $1.669 billion estimate.

Posted In: IART


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist